The discoveric bio group is excited to be launching today the all new company website and branding.
As diverse as Alzheimer's Disease (AD) and Antimicrobial Resistance (AMR) are, they carry in common a high burden on our population already now with a most gloomy outlook. Prominent failures in AD trials and a dried-out antibiotics pipeline are the drivers for these worrisome developments.
At discoveric bio we take the challenge to developing innovative solutions in these areas applying disruptive bi- and multi-specific antibody technologies with the aim to deliver safe and effective therapies to patients.
Our team at the discoveric bio group has a track record in drug development and commercialization from biotech and Big Pharma. Our expertise goes from discovery through pre-clinical and clinical development into commercial excellence.
We collaborate with a wide network of world class experts and CROs to develop and advance our pipeline in Alzheimer’s Disease and Antimicrobial Resistance.
The new website is live as of today and can be reached at www.discovericbio.com
For more information please contact us via the contact form or via email:
